Evommune EVMN
NYSE EVMN
$8.62 +0.76 (+9.67%)
At close: Nov 11, 2026 · 4:00 PM EST

Evommune (EVMN) Change in Accrued Expenses (2024 - 2026)

Updated

Evommune (EVMN) recorded Change in Accrued Expenses of $5.95 million in Q2 2026, up 361.9% from $1.29 million a year earlier.

Analysis

Evommune (EVMN) Change in Accrued Expenses (2024 - 2026) Analysis & Trends

On a TTM basis, Evommune's Change in Accrued Expenses came in at $4.77 million as of Jun 30, 2026; for FY2025, it came in at $2.82 million, up 4.2% from FY2024.

  • Across earlier years, Change in Accrued Expenses came in at $2.7 million in FY2024.
  • Per Business Quant, the preceding three quarters came in at -$4.81 million (Q1 2026), $4.3 million (Q4 2025) and -$666,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Accrued Exp. (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 2.41 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 983.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -87.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 756.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Evommune 285.17 Mn -352.34 Mn - 5.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.95 Mn
Mar 31, 2026 -4.81 Mn
Dec 31, 2025 4.30 Mn
Sep 30, 2025 -666,000.00
Jun 30, 2025 1.29 Mn
Mar 31, 2025 -2.10 Mn
Dec 31, 2024 -140,000.00
API Access

Evommune Change in Accrued Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-accured-expenses&ticker=EVMN&period=max&api_key=YOUR_API_KEY